Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 6
2004 3
2005 6
2006 2
2007 1
2008 6
2009 9
2010 1
2011 2
2012 1
2013 2
2014 1
2016 5
2017 8
2018 3
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P. Jetty V, et al. Among authors: goldenberg n. Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28740397 Free PMC article.
Progressively Worsening Premature Coronary Artery Disease: Adding Anticoagulation Stabilizes-Reverses Clinical Symptomatic Disease Progression in Thrombophilic-Atherothrombotic Patients: A Pilot Study.
Rothschild M, Jetty V, Mahida C, Wang P, Prince M, Goldenberg N, Glueck CJ. Rothschild M, et al. Among authors: goldenberg n. Clin Appl Thromb Hemost. 2017 Nov;23(8):1060-1070. doi: 10.1177/1076029617702242. Epub 2017 Apr 10. Clin Appl Thromb Hemost. 2017. PMID: 28393620 Free article. Clinical Trial.
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.
Shah P, Glueck CJ, Goldenberg N, Min S, Mahida C, Schlam I, Rothschild M, Huda A, Wang P. Shah P, et al. Among authors: goldenberg n. Lipids Health Dis. 2017 Jan 23;16(1):19. doi: 10.1186/s12944-017-0416-7. Lipids Health Dis. 2017. PMID: 28115017 Free PMC article.
51 results